Tuesday, September 13, 2022
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Data Shows Efficacy After Treatment Failures. Onconova presented positive interim data from its Phase 1/2a trial testing rigosertib at the European Society for Medical Oncology (ESMO). The Investigator-sponsored trial tested the combination of rigosertib with nivolumab, an anti-PD1 checkpoint inhibitor, in non-small cell lung cancer patients that had progressive non-small cell lung cancer (NSCLC) following treatment with checkpoint inhibitor therapies.
Patients Showed Both Complete and Partial Responses. The interim data reported was for 14 out of 19 patients enrolled in the study. Four of the 14 (29%) showed disease control responses, including 1 complete response, 2 partial responses, and 1 stable disease. Mean survival for these responders was 6.75 months, compared with 1-2 months for the non-responders. Each responding patient had a different mutation in the KRAS gene, showing activity against multiple variants.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.